Circulating taurine rises with age in humans and mice, contradicting the popular idea that falling taurine drives aging. Giving aged mice additional taurine improved healthspan, engaged anti-inflammatory pathways associated with youth, and reduced mortality from sepsis and inflammasome-driven inflammation. Mechanistically, NLRP3 danger signals trigger taurine efflux from macrophages, and restoring intracellular taurine blocks trans-Golgi network disassembly, preventing inflammasome activation and pyroptosis. In humans on sustained caloric restriction, adipose taurine increased alongside lower inflammation.
The key conceptual shift is that taurine appears to be a compensatory brake on inflammation rather than a depleted youth molecule, which helps reconcile conflicting reports on age-related taurine decline. That reframing matters for supplement users: the mouse benefit came from raising taurine above an already elevated baseline, so it does not simply justify replacing a deficiency. The evidence here is overwhelmingly from mice and cultured macrophages. The only human data are correlational, linking caloric restriction to higher adipose taurine and less inflammation, which cannot show taurine caused the benefit. No human trial yet shows that taurine supplementation lowers inflammaging or extends healthspan, and optimal dosing in people is unknown. Taurine is cheap and generally well tolerated, but this work supports further trials rather than self-experimentation. The macrophage NLRP3 mechanism is a genuinely new, testable pathway, and the caloric restriction link suggests taurine may mediate some of its anti-inflammatory effects. I rate this as a meaningful mechanistic advance, not yet actionable clinical evidence.